Immucor Message Board - Msg: 10772183

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tadsamillionaire who wrote (331)	8/1/1999 11:13:00 PM
From: Thomas Kirwin	Read Replies (1) of 422

R&A Fast Fact #7 - Instrument/Reagent Sales "Our sales estimates for the instrument line call for 120 units to be sold this year, more than doubling in FY2001 to 250. The mix is expected to be heavily weighted to the ABS2000. Reagent sales should be up by 40% in FY2000 based on our instrument forecast and increments from acquisitions, followed by a lesser gain in FY2001 as some cannibalization of manual reagent sales takes place. Gross margins should improve as the instrument/reagent trail component of sales increases, while SG&A can be leveraged as volume increases." Best O'Luck! Tom

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next